A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
David Kudrow(California Medical Clinic for Headache), Eric Pearlman(University of California, San Francisco), Linda Anh B. Nguyen(Stanford University), Deirdre B. Hoban(Eli Lilly (United States)), Chad Stroud(Eli Lilly (United States)), Hai‐An Hsu(Eli Lilly (United States)), Linda Wietecha(Eli Lilly (United States)), Jack Semler(Medtronic (United States)), Karen Samaan(Eli Lilly (United States))
Cited by 13
Related Papers
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446
Cellular Changes in Diabetic and Idiopathic Gastroparesis
|Gastroenterology|2011|445